DR. HENRY LIN, MD
Osteopathic Medicine at San Pedro Dr, Albuquerque, NM

2008013, Jun 12, 2008

Feb 13, 2008

12/030758

Mark Pimentel - Los Angeles CA, US
Henry C. Lin - Albuquerque NM, US

CEDARS-SINAI MEDICAL CENTER - Los Angeles CA

A61K 35/74

424 934

Disclosed is a method of manipulating the rate of gastrointestinal transit in a mammalian subject. Also disclosed is the use, in the manufacture of a medicament for the treatment of constipation, of a selective inhibitor of methanogensis, a methanogen-displacing probiotic agent, or a prebiotic agent that inhibits the growth of methanogenic bacteria or promotes the growth of competing non-methanogenic intestinal flora. Alternatively, in accordance with the invention, is disclosed the use in the manufacture of a medicament for the treatment of diarrhea, of methane or a methane precursor, a methanogenic or other methane-enhancing probiotic agent, or a methanogenesis-enhancing prebiotic agent.

2009023, Sep 17, 2009

Mar 23, 2006

11/909140

Henry C. Lin - Albuquerque NM, US

USC STEVENS, UNIVERSITY OF SOUTHERN CALIFORNIA - Los Angeles CA

A61K 31/606, G01N 33/50, C12Q 1/02

514166, 436121, 436119, 435 29

The present invention relates to the treatment of a wide array of diseases and physiologic conditions based on modulating the level of hydrogen sulfide (H2S) in the body by at least partially eradicating small intestinal bacterial overgrowth (SIBO) in the gut. An H2S or lactulose breath test and/or detection of H2S or thiosulfate in the blood or urine may be used as a diagnostic and/or prognostic for assessing a systemic H2S load that exceeds a mammal's natural detoxification capacity. These tests may similarly be used to monitor the effectiveness of a therapeutic intervention for SIBO and/or the diseases or physiologic conditions whose pathology is linked thereto. Because SIBO is related to hyperhomocysteinemia, diseases and physiologic conditions that relate to hyperhomocysteinemia may further be monitored and treated in connection with the methods of the present invention.

8388935, Mar 5, 2013

Dec 9, 2011

13/315671

Henry C. Lin - Albuquerque NM, US
Mark Pimentel - Los Angeles CA, US

Cedars-Sinai Medical Center - Los Angeles CA

A61K 49/00, A61K 35/00, A61K 45/00

424 92, 424 91, 424116, 4242781, 424439, 426 5, 426 71, 426658, 426800, 435 5, 435 29

Disclosed is a method of treating small intestinal bacterial overgrowth (SIBO) or a SIBO-caused condition in a human subject. SIBO-caused conditions include irritable bowel syndrome, fibromyalgia, chronic pelvic pain syndrome, chronic fatigue syndrome, depression, impaired mentation, impaired memory, halitosis, tinnitus, sugar craving, autism, attention deficit/hyperactivity disorder, drug sensitivity, an autoimmune disease, and Crohn's disease. Also disclosed are a method of screening for the abnormally likely presence of SIBO in a human subject and a method of detecting SIBO in a human subject. A method of determining the relative severity of SIBO or a SIBO-caused condition in a human subject, in whom small intestinal bacterial overgrowth (SIBO) has been detected, is also disclosed.

8197805, Jun 12, 2012

Mar 28, 2011

13/073169

Henry C. Lin - Albuquerque NM, US
Mark Pimentel - Los Angeles CA, US

Cedars-Sinai Medical Center - Los Angeles CA

A01N 63/00, A61K 35/00

424 931, 424114, 424116

Disclosed is a method of diagnosing autoimmune diseases, such as multiple sclerosis and systemic lupus erythematosus, which involves detecting the presence of small intestinal bacterial overgrowth (SIBO) in a human subject having at least one symptom associated with a suspected diagnosis an autoimmune disease. Also disclosed is a method of treating these autoimmune diseases, which involves at least partially eradicating a SIBO condition in the human subject. The method includes administration of antimicrobial or probiotic agents, or normalizing intestinal motility by employing a prokinetic agent. Also disclosed is a kit for the diagnosis or treatment of autoimmune diseases.

8110177, Feb 7, 2012

Apr 27, 2010

12/768531

Henry C. Lin - Albuquerque NM, US
Mark Pimentel - Los Angeles CA, US

Cedars-Sinai Medical Center - Los Angeles CA

A61K 49/00, A61K 45/00, A61K 47/00

424 92, 424 91, 424116, 4242781, 424439, 426 5, 426 71, 426658, 426800, 426801, 435 4, 435 29

Disclosed is a method of treating small intestinal bacterial overgrowth (SIBO) or a SIBO-caused condition in a human subject. SIBO-caused conditions include irritable bowel syndrome, fibromyalgia, chronic pelvic pain syndrome, chronic fatigue syndrome, depression, impaired mentation, impaired memory, halitosis, tinnitus, sugar craving, autism, attention deficit/hyperactivity disorder, drug sensitivity, an autoimmune disease, and Crohn's disease. Also disclosed are a method of screening for the abnormally likely presence of SIBO in a human subject and a method of detecting SIBO in a human subject. A method of determining the relative severity of SIBO or a SIBO-caused condition in a human subject, in whom small intestinal bacterial overgrowth (SIBO) has been detected, is also disclosed.

8562952, Oct 22, 2013

Mar 1, 2013

13/782504

Henry C. Lin - Albuquerque NM, US

Cedars-Sinai Medical Center - Los Angeles CA

A61K 49/00, A61K 35/00, A61K 45/00

424 92, 424 91, 424116, 4242781, 424439, 426 5, 426 71, 426658, 426800, 435 5, 435 29

Various embodiments of the invention disclosed herein include methods of inducing satiety a mammal in need thereof. Also disclosed are methods of inducing satiety in an obese mammal. Additionally disclose are method of suppressing appetite in a mammal in need thereof. Further disclosed are methods of treating obesity. The methods described herein involve the administration of serotonin, a serotonin agonist or a serotonin re-uptake inhibitor to the mammal.